MedTrace Logo

Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study

NCT04975932 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 826

Last updated 2023-07-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .

Conditions

Interventions

OTHER

TACE+ICIs

TACE plus ICIs ( with or without molecular targeted therapies)

PROCEDURE

TACE

TACE without combination of ICIs ( with or without molecular targeted therapies)

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Gao-Jun Teng, MD · Zhongda hospital, Southeast university, Nanjing, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-05-31
Completion
2023-02-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975932 on ClinicalTrials.gov